Dr. Stephen J. Russell, Vyriad, CEO; Dr. Kah-Whye Peng, Vyriad, CTO; Dr. Luke Russell, Vyriad, Director of Alliance Management and Vino Raj, Vyriad, Medical Director, attended the Annual IOVC in Sedona, AZ. Dr. Kah Whye Peng was presented with the Golden Virus Award for her outstanding contribution to the field of virotherapy.
The following presentations all addressed Vyriad technologies, including both clinical and preclinical programs:
Shruthi Naik, Ph.D., Vyriad
Safety and Efficacy of Neoadjuvant Intravesical Oncolytic MV-NIS in Patients with Urothelial Carcinoma
Miguel A Muñoz Alía, Ph.D., Vyriad
Measles Virus, Stealthed and Retargeted
Read presentation
Rianna Vandergaast, Ph.D., Imanis Life Sciences
Using the IMMUNO-COV Clinical Assay for SARS-CoV-2-Neutralizing Antibodies to Track Titer Declines in Individuals Following Vaccination
View presentation
Joselle Cook, M.D., Mayo Clinic
Clinical Activity of Systemic VSV-IFNβ-NIS Oncolytic Virotherapy in Patients with Hematologic Malignancies
Read presentation
Evanthia Galanis, M.D., Mayo Clinic
First in Human Testing of Measles Virus Infected Mesenchymal Stem Cells
Haifei Jiang, Ph.D., Mayo Clinic
Herpes viral Combination Therapy for Targeting Both Cancer Cells and Cancer Associated Stromal Cells
View presentation
Richard Vile, Ph.D., Mayo Clinic
Combining CAR-T Cell Therapy with Oncolytic Viruses
View presentation
Karol Budzik, Ph.D., Mayo Clinic
Development and Characterization of a Foamy Virus-Based Oncolytic Replicating Retroviral Vector
Read presentation
Autumn Schulze, Ph.D., Mayo Clinic
Synthetic Infectious RNA-Based Oncolytic Immunotherapy
View presentation
Media Inquiries
For inquiries, please contact mediarelations@vyriad.com